Disease · MONDO_0019735
polymyalgia rheumatica
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. polymyalgia rheumatica. Diseases, record MONDO_0019735. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019735
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 5 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| SECUKINUMAB | CHEMBL1743068 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TOFACITINIB | CHEMBL221959 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ABATACEPT | CHEMBL1201823 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETANERCEPT | CHEMBL1201572 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INFLIXIMAB | CHEMBL1201581 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets18
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 2 | Interleukin-6 receptor alpha subunit antagonist; Interleukin-6 receptor alpha subunit inhibitor | Phase 3 | https://conductscience.org/library/genes/3570 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 3 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 3 | https://conductscience.org/library/genes/942 | Drugs and targets |
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | 1 | Dihydroorotate dehydrogenase inhibitor | Phase 3 | https://conductscience.org/library/genes/1723 | Drugs and targets |
| IL17A | Interleukin-17A | 1 | Interleukin 17A inhibitor | Phase 3 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| IL1B | Interleukin-1 beta | 1 | Interleukin-1 beta inhibitor | Phase 2 | https://conductscience.org/library/genes/3553 | Drugs and targets |
1 to 10 of 18
See all 18 targetsTrials32
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04972968 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 | Phase 2 | 181 | 2024-10-15 | Polymyalgia Rheumatica | ADALIMUMAB FOSIMDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03600818 | Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica | Phase 3 | 118 | 2022-06-10 | Polymyalgia Rheumatica | SARILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01364389 | A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica | Phase 2 | 16 | 2015-03-04 | Polymyalgia Rheumatica, Inflammatory Diseases | CANAKINUMAB, PREDNISONE, SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00836810 | Timed Release Tablet Prednisone in Polymyalgia Rheumatica | Phase 2/3 | 12 | 2018-02-05 | Polymyalgia Rheumatica | PREDNISOLONE, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT01396317 | Study of Tocilizumab to Treat Polymyalgia Rheumatica | Phase 2 | 10 | 2018-01-17 | Polymyalgia Rheumatica (PMR) | TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03760562 | The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory Diseases | 111,804 | Hypertension | PREDNISOLONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT05767034 | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) | Phase 3 | 381 | Polymyalgia Rheumatica | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05533164 | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse | Phase 3 | 174 | Polymyalgia Rheumatica | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06331312 | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | Phase 3 | 162 | Polymyalgia Rheumatica | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07279688 | Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica | Phase 3 | 140 | Polymyalgia Rheumatica (PMR) | BARICITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 32
See all 32 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Placebo+52 Week Taper vs Sarilumab 200mg q2w+14 Week Taper: Number of Participants With Sustained Reduction of CRP From Week 12 Through Week 52 | 26 of 58 | 40 of 60 | 118 | NCT03600818 | Trial comparisons |
| Placebo+52 Week Taper vs Sarilumab 200mg q2w+14 Week Taper: Number of Participants Who Achieved Disease Remission up to Week 12 | 22 of 58 | 28 of 60 | 118 | NCT03600818 | Trial comparisons |
| Placebo+52 Week Taper vs Sarilumab 200mg q2w+14 Week Taper: Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52 | 14 of 58 | 30 of 60 | 118 | NCT03600818 | Trial comparisons |
| Placebo+52 Week Taper vs Sarilumab 200mg q2w+14 Week Taper: Number of Participants With Absence of Disease Flare From Week 12 Through Week 52 | 19 of 58 | 33 of 60 | 118 | NCT03600818 | Trial comparisons |
| Placebo+52 Week Taper vs Sarilumab 200mg q2w+14 Week Taper: deaths from any cause | 0 of 58 | 0 of 59 | 117 | NCT03600818 | Trial comparisons |
| Placebo+52 Week Taper vs Sarilumab 200mg q2w+14 Week Taper: serious adverse events | 12 of 58 | 8 of 59 | 117 | NCT03600818 | Trial comparisons |
| Tocilizumab + Corticosteroid Taper vs Control (Corticosteroid Taper Alone): Proportion of Patients in Disease Remission at Six Months From Trial Entry | 9 of 9 | 0 of 10 | 19 | NCT01396317 | Trial comparisons |
| Tocilizumab + Corticosteroid Taper vs Control (Corticosteroid Taper Alone): Proportion of Patients Who Develop Disease Relapses | 0 of 9 | 10 of 10 | 19 | NCT01396317 | Trial comparisons |
| Timed Release Tablet Prednisone vs Standard Prednisolone: deaths from any cause | 0 of 4 | 0 of 6 | 10 | NCT00836810 | Trial comparisons |
| Timed Release Tablet Prednisone vs Standard Prednisolone: serious adverse events | 0 of 4 | 0 of 6 | 10 | NCT00836810 | Trial comparisons |
Papers from its trials19
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019735
GET https://conductscience.org/api/diseases/v1/MONDO_0019735/drugs?page=2